Willy A Flegel1. 1. Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland.
Abstract
BACKGROUND: The clinical consequences of antibodies to red blood cells (RBCs) have been studied for a century. Most clinically relevant antibodies can be detected by sensitive in vitro assays. Several mechanisms of antibody-mediated hemolysis are well understood. Such hemolysis after transfusion is reliably avoided in a donor-recipient pair, if one individual is negative for the cognate antigen to which the other has the antibody. STUDY DESIGN AND RESULTS: Mechanisms of antibody-mediated hemolysis were reviewed based on a presentation at the Strategies to Address Hemolytic Complications of Immune Globulin Infusions Workshop addressing intravenous immunoglobulin (IVIG) and ABO antibodies. The presented topics included the rates of intravascular and extravascular hemolysis; immunoglobulin (Ig)M and IgG isoagglutinins; auto- and alloantibodies; antibody specificity; A, B, A,B, and A1 antigens; A1 versus A2 phenotypes; monocytes-macrophages, other immune cells, and complement; monocyte monolayer assay; antibody-dependent cell-mediated cytotoxicity; and transfusion reactions due to ABO and other antibodies. CONCLUSION: Several clinically relevant questions remained unresolved, and diagnostic tools were lacking to routinely and reliably predict the clinical consequences of RBC antibodies. Most hemolytic transfusion reactions associated with IVIG were due to ABO antibodies. Reducing the titers of such antibodies in IVIG may lower the frequency of this kind of adverse event. The only way to stop these events is to have no anti-A or anti-B in the IVIG products.
BACKGROUND: The clinical consequences of antibodies to red blood cells (RBCs) have been studied for a century. Most clinically relevant antibodies can be detected by sensitive in vitro assays. Several mechanisms of antibody-mediated hemolysis are well understood. Such hemolysis after transfusion is reliably avoided in a donor-recipient pair, if one individual is negative for the cognate antigen to which the other has the antibody. STUDY DESIGN AND RESULTS: Mechanisms of antibody-mediated hemolysis were reviewed based on a presentation at the Strategies to Address Hemolytic Complications of Immune Globulin Infusions Workshop addressing intravenous immunoglobulin (IVIG) and ABO antibodies. The presented topics included the rates of intravascular and extravascular hemolysis; immunoglobulin (Ig)M and IgG isoagglutinins; auto- and alloantibodies; antibody specificity; A, B, A,B, and A1 antigens; A1 versus A2 phenotypes; monocytes-macrophages, other immune cells, and complement; monocyte monolayer assay; antibody-dependent cell-mediated cytotoxicity; and transfusion reactions due to ABO and other antibodies. CONCLUSION: Several clinically relevant questions remained unresolved, and diagnostic tools were lacking to routinely and reliably predict the clinical consequences of RBC antibodies. Most hemolytic transfusion reactions associated with IVIG were due to ABO antibodies. Reducing the titers of such antibodies in IVIG may lower the frequency of this kind of adverse event. The only way to stop these events is to have no anti-A or anti-B in the IVIG products.
Authors: Dereddi Raja S Reddy; Pramod K Guru; Melissa M Blessing; James R Stubbs; Alejandro A Rabinstein; Eelco F M Wijdicks Journal: Neurocrit Care Date: 2015-10 Impact factor: 3.210
Authors: Willy A Flegel; Shirley L De Castilho; Margaret A Keller; Ellen B Klapper; Joann M Moulds; France Noizat-Pirenne; Nadine Shehata; Gary Stack; Maryse St-Louis; Christopher A Tormey; Dan A Waxman; Christof Weinstock; Silvano Wendel; Gregory A Denomme Journal: Blood Transfus Date: 2015-12-21 Impact factor: 3.443
Authors: Willy A Flegel; Lilian Castilho; Wm Andrew L Heaton; Margaret A Keller; Ellen B Klapper; William J Lane; France Pirenne; Nadine Shehata; Gary Stack; Maryse St-Louis; Christopher A Tormey; Franz F Wagner; Dan A Waxman; Gregory A Denomme Journal: Blood Transfus Date: 2016-07-29 Impact factor: 3.443
Authors: Willy A Flegel; Qing Chen; Lilian Castilho; Margaret A Keller; Ellen B Klapper; William J Lane; France Pirenne; Gary Stack; Maryse St-Louis; Christopher A Tormey; Dan A Waxman; Christof Weinstock; Silvano Wendel; Gregory A Denomme Journal: Blood Transfus Date: 2018-02-14 Impact factor: 3.443
Authors: Randin C Nelson; Vicki Fellowes; Ping Jin; Hui Liu; Steven L Highfill; Jiaqiang Ren; James Szymanski; Willy A Flegel; David F Stroncek Journal: Transfusion Date: 2020-03-13 Impact factor: 3.337
Authors: M Jalink; E C W de Boer; D Evers; M Q Havinga; J M I Vos; S Zeerleder; M de Haas; I Jongerius Journal: Semin Immunopathol Date: 2021-06-30 Impact factor: 9.623